How siRNA Technology Targets Disease-Causing Genes in Inflammation and Cancer

By Dr. Priyom Bose, Ph.D.Reviewed by Lauren Hardaker

Introduction
siRNA-Mediated Gene Silencing
How do siRNAs Promote Programmable Immune Modulation?
Benefits of siRNA Therapeutics Over Conventional Therapies in Inflammatory Disease
Barriers, Safety Considerations, and Future Outlook
References

Introduction

siRNAs function through intracellular RNA interference machinery to degrade target mRNA, enabling sustained and catalytic suppression of gene expression across diverse disease pathways. By reshaping immune signaling networks and overcoming limitations of protein-targeting drugs, they offer a versatile platform for precision therapeutics while highlighting the need for improved delivery and specificity. 

Image credit: nobeastsofierce/Shutterstock.com

Short interfering RNAs (siRNAs) represent one of the most transformative advances in molecular medicine, offering an unprecedented ability to silence virtually any disease-causing gene with sequence-level precision.¹ This therapeutic potential has translated into clinical reality, with multiple siRNA-based drugs approved since 2018, beginning with patisiran, and additional agents targeting metabolic and cardiovascular diseases, reflecting the rapid clinical expansion of RNA interference-based therapies.¹¹

siRNA-Mediated Gene Silencing

RNAi is a conserved post-transcriptional gene silencing mechanism, first described in Caenorhabditis elegans in 1998, in which small double-stranded RNA (dsRNA) molecules engage the cell’s endogenous silencing machinery to selectively degrade complementary mRNA targets and suppress their translation. This mechanism was later demonstrated in mammalian systems in 2001, enabling its translation into therapeutic applications.^2,11

siRNAs are chemically synthesized duplexes of 21–23 base pairs with characteristic 2-nucleotide 3′ overhangs, designed to achieve full complementarity to their target transcript and achieve precise, sequence-specific silencing. These structural features are critical to prevent activation of interferon responses, which are typically triggered by longer dsRNA molecules.³

Their therapeutic utility is further reinforced through chemical modifications, including 2’-O-methyl (2’-OMe), phosphorothioate (PS) backbone substitutions, and 2’-fluoro (2’-F), which collectively improve nuclease resistance, immune evasion, and target specificity, broadening their applicability in vivo and in clinical settings. Short hairpin RNAs (shRNAs) represent an alternative, vector-encoded effector class that converges on the same silencing machinery following intracellular Dicer processing.

Once delivered to the cytoplasm, siRNA duplexes are loaded into the RNA-induced silencing complex (RISC), where the sense (passenger) strand is ejected, and the antisense (guide) strand directs the complex to complementary mRNA targets.⁴ The catalytic subunit Argonaute 2 (AGO2) then cleaves the transcript between positions 10 and 11 relative to the guide strand’s 5′ end, marking it for rapid exonucleolytic degradation. This catalytic mechanism enables a single siRNA-loaded RISC complex to cleave multiple mRNA molecules, contributing to the potency and durability of gene silencing.³

How do siRNAs Promote Programmable Immune Modulation?

By exploiting RNAi, siRNAs selectively silence disease-driving genes without broadly disrupting cellular function. This strategy offers precision, enabling them to reprogram immune cell behavior in ways conventional drugs cannot: silencing co-inhibitory checkpoints such as programmed death-ligand 1 (PD-L1), depleting immunosuppressive regulatory T cells (Tregs), and redirecting macrophage activity away from tumor support.¹

Mechanistically, siRNAs targeting immune checkpoint genes, including programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), block the molecular off-switches that tumors exploit to evade immune detection, restoring the cytolytic capacity of cytotoxic T lymphocytes (CTLs) and reversing T cell exhaustion. Suppression of PD-1/PD-L1 signaling has been shown to enhance T-cell activation, antigen presentation, and reduce tumor-mediated immunosuppression.⁵

Within the tumor microenvironment (TME), tumor-associated macrophages (TAMs) are frequently polarized toward an immunosuppressive M2 (alternatively activated)-like phenotype.⁶ siRNA-mediated silencing of regulatory genes, such as USP7 or inhibitor of nuclear factor kappa-B kinase subunit beta (IKKβ), can re-educate these cells toward a pro-inflammatory M1 (classically activated)-like state, restoring their capacity for antigen presentation and tumor cell clearance. This reprogramming is critical because M2-polarized macrophages support tumor progression, whereas M1 macrophages promote anti-tumor immunity.^6,7

siRNAs can also suppress immunosuppressive cytokines, particularly interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), dismantling the suppressive TME niche and licensing effector T cells and natural killer (NK) cells to mount an anti-tumor response. For example, silencing TGF-β1 has been shown to reduce regulatory T cell populations and enhance tumor-infiltrating effector T cells.⁸ Beyond direct immune modulation, siRNAs can be engineered to trigger immunogenic cell death (ICD) in tumor cells, a process that liberates damage-associated molecular patterns (DAMPs) and tumor-associated antigens, activating dendritic cells and priming a durable, systemic adaptive immune response. This process converts immunologically “cold” tumors into “hot” tumors with increased immune responsiveness.⁹

Benefits of siRNA Therapeutics Over Conventional Therapies in Inflammatory Disease

Conventional treatments for inflammatory diseases, such as inflammatory bowel disease (IBD) and psoriasis, include corticosteroids, immunomodulators, and biologics. These treatments act at the protein level, broadly suppressing immune activity rather than correcting the underlying molecular drivers of pathology. This lack of specificity contributes to systemic immunosuppression, treatment resistance, and inadequate remission rates in a considerable proportion of patients.

siRNA therapeutics represent a mechanistically distinct approach, acting upstream at the mRNA level to silence the specific transcripts that sustain inflammatory signaling before pathological proteins are produced.³ Because siRNAs bind only their complementary target messenger RNA (mRNA), they achieve sequence-specific gene silencing with minimal off-target activity. Additionally, RNAi enables targeting of genes that are not amenable to conventional small-molecule or antibody-based therapies.¹¹

In conditions such as Crohn’s disease or systemic lupus erythematosus (SLE), where pathological immune signaling is driven by discrete mediators including Tumor Necrosis Factor-alpha (TNF-α), IL-6, and Nuclear Factor- κB (NF-κB), siRNA therapeutics' selectivity allows suppression of disease-relevant targets without broadly impairing immune homeostasis. RNAi-based approaches have demonstrated the ability to suppress multiple inflammatory signaling pathways simultaneously at the gene expression level.¹⁰

Conventional pharmacology is further constrained by its dependence on ligandable protein structures; many transcription factors and intracellular proteins central to chronic inflammation, including components of the NF-κB and JAK/STAT pathways, lack accessible binding pockets for small molecules and are poorly suited to antibody-based targeting. siRNA bypasses this structural constraint by acting at the mRNA level, making a far wider range of disease-driving genes therapeutically accessible.

Beyond target accessibility, siRNAs offer meaningful advantages in terms of design flexibility and durability of effect. Their sequences can be rapidly adapted once a disease-associated gene sequence is known, enabling faster therapeutic development compared to traditional drug discovery pipelines.¹¹ Their sequences can be rapidly designed and chemically optimized against any validated mRNA target, with modifications such as 2’-OMe, PS, and 2’-F enhancing nuclease resistance, immune evasion, and target engagement. The catalytic efficiency of RISC-mediated silencing further translates into prolonged pharmacodynamic activity from a relatively low effective dose.

Video credit: UNSW/Shutterstock.com

Barriers, Safety Considerations, and Future Outlook

The clinical advancement of siRNA therapeutics has been accompanied by a growing understanding of their safety profile. siRNA molecules are generally well tolerated, but several safety concerns have been identified. Off-target silencing occurs when the siRNA sequence partially matches unintended messenger RNA transcripts, leading to suppression of genes that were not the intended target.¹¹ This can result in unpredictable biological effects and represents one of the most significant safety challenges in siRNA development. Chemical modifications improve specificity and reduce off-target activity.

Immune activation is another concern, as certain siRNA sequences can stimulate innate immune receptors, including toll-like receptors, triggering inflammatory responses. This immunostimulatory effect is sequence- and structure-dependent and can be mitigated through rational design and chemical modification.³ Careful sequence design and chemical modification strategies have reduced, but not eliminated, this risk.

Additional barriers include rapid degradation by nucleases, poor cellular uptake, and inefficient delivery to target tissues, necessitating the development of advanced delivery systems such as lipid nanoparticles and conjugate-based platforms.⁴

Despite these challenges, the future of siRNA therapeutics is highly promising. The approval of multiple siRNA drugs within a short period has validated the platform and accelerated investment in next-generation delivery technologies. As delivery barriers are progressively overcome, siRNA therapeutics are poised to become a cornerstone of precision medicine, offering a programmable, broadly applicable approach to silencing genes that cause disease.

References

1. Zhang J, et al. A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy. Int J Nanomedicine. 2023;18:7605-7635. DOI:10.2147/IJN.S436038, https://www.dovepress.com/a-comprehensive-review-of-small-interfering-rnas-sirnas-mechanism-ther-peer-reviewed-fulltext-article-IJN.
2. Ozcan G, et al. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015;87:108-19. DOI:10.1016/j.addr.2015.01.007, https://www.sciencedirect.com/science/article/abs/pii/S0169409X15000095.
3. Ebenezer O, et al. Recent Update on siRNA Therapeutics. Int J Mol Sci. 2025;26(8):3456. DOI:10.3390/ijms26083456, https://www.mdpi.com/1422-0067/26/8/3456.
4. Paul A, et al. SiRNA therapeutics and its challenges: Recent advances in effective delivery for cancer therapy. OpenNano. 2022; 7, 100063. DOI:10.1016/j.onano.2022.100063, https://www.sciencedirect.com/science/article/pii/S2352952022000251
5. Barati M, et al. A review of PD-1/PD-L1 siRNA delivery systems in immune T cells and cancer cells. Int Immunopharmacol. 2022;111:109022. DOI:10.1016/j.intimp.2022.109022, https://www.sciencedirect.com/science/article/abs/pii/S1567576922005069.
6. Zou Z, et al. Tumor-associated macrophage polarization in the inflammatory tumor microenvironment. Front Oncol. 2023;13:1103149. DOI:10.3389/fonc.2023.1103149, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1103149/full.
7. Qin B, Cheng K. Silencing of the IKKε gene by siRNA inhibits invasiveness and growth of breast cancer cells. Breast Cancer Res. 2010;12(5):R74. DOI:10.1186/bcr2644, https://link.springer.com/article/10.1186/bcr2644.
8. Conroy H, et al. Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells. Cancer Immunol Immunother. 2012;61(3):425-31. DOI:10.1007/s00262-011-1188-y, https://link.springer.com/article/10.1007/s00262-011-1188-y.
9. Zhang T, et al. NIR-II photo-accelerated polymer nanoparticles boost tumor immunotherapy via PD-L1 silencing and immunogenic cell death. Bioactive Materials. 2025; 46, 285-300. DOI:10.1016/j.bioactmat.2024.12.018, https://www.sciencedirect.com/science/article/pii/S2452199X24005330
10. Sargazi S, et al. siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review. Cell Biol Int. 2022;46(9):1320-1344. DOI:10.1002/cbin.11841, https://onlinelibrary.wiley.com/doi/10.1002/cbin.11841.
11. Liu M, et al. Landscape of small nucleic acid therapeutics: Moving from the bench to the clinic as next-generation medicines. Signal Transduct Target Ther. 2025;10(1):73. DOI:10.1038/s41392-024-02112-8, https://www.nature.com/articles/s41392-024-02112-8

Last Updated: Mar 26, 2026